Please login to the form below

Not currently logged in
Email:
Password:

Roche acquires innovatis AG

Roche announced today that it has signed a definite agreement to acquire 100 per cent of innovatis, a privately held company based in Bielefeld, Germany

Roche announced today that it has signed a definite agreement to acquire 100 per cent of innovatis, a privately held company based in Bielefeld, Germany. The acquisition, which is valued at €15m, is aimed at complementing Roche's product portfolio in the rapidly growing area of cellular analytics.

Innovatis is a leading provider of automated cell analysis solutions, especially focusing on cell counting, viability testing, and cell function analysis in research, as well as bioproduction. According to Dr Jürgen Schwiezer, CEO Division Roche Diagnostics, the move is a further step in the company's strategy to strengthen its position as a "complete solution provider in the cell analysis research market", and is "synergistic to the xCELLigence technology," launched by Roche Applied Science in 2008 to enable researchers to monitor cell activities in real time.

Under the terms of the agreement, innovatis is to become a fully-integrated part of Roche Applied Science, a global business area of the Diagnostic Division of Roche. The company will continue to develop and market products for cell analysis through Roche Applied Science's extensive worldwide network. The transaction is expected to be completed within the next few weeks, subject to shareholder approval and regulatory clearance.

16th March 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics